

Rajesh T Gandhi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7037836/publications.pdf>

Version: 2024-02-01

84
papers

5,089
citations

186209

28
h-index

95218

68
g-index

87
all docs

87
docs citations

87
times ranked

8318
citing authors

#	ARTICLE	IF	CITATIONS
1	Mild or Moderate Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 1757-1766.	13.9	1,087
2	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2020, , .	2.9	708
3	The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial. <i>PLoS Medicine</i> , 2010, 7, e1000321.	3.9	258
4	The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. <i>Aids</i> , 2015, 30, 1.	1.0	214
5	HIV-1 DNA Decay Dynamics in Blood During More Than a Decade of Suppressive Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2014, 59, 1312-1321.	2.9	203
6	Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive Subjects. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 42, 426-434.	0.9	148
7	Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. <i>PLoS Pathogens</i> , 2017, 13, e1006285.	2.1	147
8	Immunologic Control of HIV-1. <i>Annual Review of Medicine</i> , 2002, 53, 149-172.	5.0	140
9	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. <i>Lancet HIV</i> , 2019, 6, e259-e268.	2.1	139
10	The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. <i>Journal of Infectious Diseases</i> , 2018, 218, 1954-1963.	1.9	130
11	Progressive Reversion of Human Immunodeficiency Virus Type 1 Resistance Mutations In Vivo after Transmission of a Multiply Drug-Resistant Virus. <i>Clinical Infectious Diseases</i> , 2003, 37, 1693-1698.	2.9	125
12	Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy. <i>Journal of Virology</i> , 2016, 90, 1369-1376.	1.5	121
13	Response to Hepatitis B Vaccine in HIV-1-Positive Subjects Who Test Positive for Isolated Antibody to Hepatitis B Core Antigen: Implications for Hepatitis B Vaccine Strategies. <i>Journal of Infectious Diseases</i> , 2005, 191, 1435-1441.	1.9	103
14	No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1-Infected Patients Receiving Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 229-235.	0.9	95
15	Isolated Antibody to Hepatitis B Core Antigen in Human Immunodeficiency Virus Type-1-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2003, 36, 1602-1605.	2.9	89
16	Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance. <i>Journal of Clinical Investigation</i> , 2019, 129, 3339-3346.	3.9	81
17	Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2021, 223, 225-233.	1.9	80
18	A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. <i>Vaccine</i> , 2009, 27, 6088-6094.	1.7	79

#	ARTICLE	IF	CITATIONS
19	Prolonged viral suppression with anti-HIV-1 antibody therapy. <i>Nature</i> , 2022, 606, 368-374.	13.7	75
20	Disproportionate burden of coronavirus disease 2019 among racial minorities and those in congregate settings among a large cohort of people with HIV. <i>Aids</i> , 2020, 34, 1781-1787.	1.0	74
21	Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 246-253.	0.9	72
22	Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18692-18700.	3.3	67
23	No Evidence for Decay of the Latent Reservoir in HIV-1-Infected Patients Receiving Intensive Enfuvirtide-Containing Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2010, 201, 293-296.	1.9	64
24	Antiretroviral Therapy-Associated Toxicities in the Resource-Poor World: The Challenge of a Limited Formulary. <i>Journal of Infectious Diseases</i> , 2007, 196, S449-S456.	1.9	57
25	COVID-19 Therapeutics for Nonhospitalized Patients. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 617.	3.8	54
26	Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2016, 213, 556-560.	1.9	43
27	Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. <i>Journal of Infectious Diseases</i> , 2017, 216, 254-262.	1.9	41
28	HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. <i>JCI Insight</i> , 2021, 6, .	2.3	40
29	A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2021, 224, 648-656.	1.9	31
30	Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. <i>Clinical Infectious Diseases</i> , 2022, 74, 865-870.	2.9	30
31	HIV Online Provider Education (HOPE): The Internet as a Tool for Training in HIV Medicine. <i>Journal of Infectious Diseases</i> , 2007, 196, S512-S515.	1.9	27
32	Update on Opportunistic Infections in the Era of Effective Antiretroviral Therapy. <i>Infectious Disease Clinics of North America</i> , 2014, 28, 501-518.	1.9	27
33	Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA. <i>Journal of Virology</i> , 2018, 92, .	1.5	24
34	Metabolic and Cardiovascular Complications in HIV-Infected Patients: New Challenges for a New Age. <i>Journal of Infectious Diseases</i> , 2012, 205, S353-S354.	1.9	21
35	T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy. <i>Aids</i> , 2020, 34, 15-24.	1.0	21
36	Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 268-282.	0.5	21

#	ARTICLE	IF	CITATIONS
37	Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. <i>Vaccine</i> , 2018, 36, 453-460.	1.7	19
38	The Multidimensional Challenge of Treating Coronavirus Disease 2019 (COVID-19): Remdesivir Is a Foot in the Door. <i>Clinical Infectious Diseases</i> , 2021, 73, e4175-e4178.	2.9	18
39	When Epidemics Collide: Why People With Human Immunodeficiency Virus May Have Worse Coronavirus Disease 2019 Outcomes and Implications for Vaccination. <i>Clinical Infectious Diseases</i> , 2021, 72, e1030-e1034.	2.9	17
40	The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates. <i>HIV Clinical Trials</i> , 2017, 18, 149-155.	2.0	16
41	Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART. <i>Journal of Infectious Diseases</i> , 2018, 218, 234-238.	1.9	16
42	Lessons Learned from Coronavirus Disease 2019 (COVID-19) Therapies: Critical Perspectives From the Infectious Diseases Society of America (IDSA) COVID-19 Treatment Guideline Panel. <i>Clinical Infectious Diseases</i> , 2022, 74, 1691-1695.	2.9	16
43	Realizing the Potential of Anti-“SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 427.	3.8	16
44	Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection. <i>Current Opinion in Immunology</i> , 2002, 14, 487-494.	2.4	13
45	Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, e27-e31.	0.9	13
46	<i>Mycobacterium decipiens</i> sp. nov., a new species closely related to the <i>Mycobacterium tuberculosis</i> complex. <i>International Journal of Systematic and Evolutionary Microbiology</i> , 2018, 68, 3557-3562.	0.8	13
47	Brief Report: HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated With HIV DNA and HIV-Specific T-Cell Responses. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 594-599.	0.9	12
48	Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2: What Goes Around May Come Back Around. <i>Clinical Infectious Diseases</i> , 2021, 73, e3009-e3012.	2.9	12
49	Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption. <i>Pathogens and Immunity</i> , 2017, 2, 431.	1.4	12
50	Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-Week Results of AIDS Clinical Trials Group A5241 (OPTIONS). <i>Journal of Infectious Diseases</i> , 2020, 221, 1407-1415.	1.9	11
51	Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria. <i>Aids</i> , 2021, 35, 2225-2227.	1.0	11
52	The significance of pressure injuries and purpura in COVID-19 patients hospitalized at a large urban academic medical center: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 462-464.	0.6	10
53	Tenosynovitis Caused by a Novel Nontuberculous <i>Mycobacterium</i> Species Initially Misidentified as a Member of the <i>Mycobacterium tuberculosis</i> Complex. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4414-4418.	1.8	9
54	Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2021, 223, 462-470.	1.9	9

#	ARTICLE	IF	CITATIONS
55	The Search for an HIV Cure: Where Do We Go From Here?. <i>Journal of Infectious Diseases</i> , 2021, 223, S1-S3.	1.9	9
56	Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, 1389-1396.	2.9	9
57	Residual plasma viremia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173. <i>Antiviral Therapy</i> , 2013, 18, 607-13.	0.6	8
58	HLA Class I Alleles Associated with Mortality in Thai Military Recruits with HIV-1 CRF01_AE Infection. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 44-49.	0.5	8
59	The effect of age on CD4+ T-cell recovery in HIV-suppressed adult participants: a sub-study from AIDS Clinical Trial Group (ACTG) A5321 and the Bone Loss and Immune Reconstitution (BLIR) study. <i>Immunity and Ageing</i> , 2022, 19, 4.	1.8	8
60	Thrombosis and Coronavirus Disease 2019: Controversies and (Tentative) Conclusions. <i>Clinical Infectious Diseases</i> , 2021, 73, 2294-2297.	2.9	7
61	The Sooner, the Better: More Evidence That Early Antiretroviral Therapy Lowers Viral Reservoirs in HIV-Infected Infants. <i>Journal of Infectious Diseases</i> , 2014, 210, 1519-1522.	1.9	6
62	False-Positive Human Immunodeficiency Virus Test Results in Patients Receiving Lentivirus-Based Chimeric Antigen Receptor T-Cell Therapy: Case Report, Review of the Literature, and Proposed Recommendations. <i>Journal of Infectious Diseases</i> , 2022, 225, 1933-1936.	1.9	6
63	Whoâ€™s slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on firstâ€™line HIV treatment in Uganda and South Africa. <i>HIV Medicine</i> , 2022, 23, 474-484.	1.0	5
64	Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 757846.	1.8	5
65	Multimodal Investigation of Neuroinflammation in Aviremic Patients With HIV on Antiretroviral Therapy and HIV Elite Controllers. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	5
66	Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 489-501.	0.5	4
67	Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 510-517.	0.5	4
68	Case 9-2018: A 55-Year-Old Man with HIV Infection and a Mass on the Right Side of the Face. <i>New England Journal of Medicine</i> , 2018, 378, 1143-1152.	13.9	3
69	HIV DNA decay during antiretroviral therapy. <i>Aids</i> , 2018, 32, 2255-2257.	1.0	3
70	Desperate Times Call for Temperate Measures: Practicing Infectious Diseases During a Novel Pandemic. <i>Journal of Infectious Diseases</i> , 2020, 222, 1084-1085.	1.9	3
71	Proposing Minimum Requirements for Announcing Clinical Trial Results During the COVID-19 Pandemic. <i>Clinical Infectious Diseases</i> , 2021, 72, 1265-1267.	2.9	3
72	Disparities in SARS-CoV-2 Vaccination-to-Infection Risk During the COVID-19 Pandemic in Massachusetts. <i>JAMA Health Forum</i> , 2021, 2, e212666.	1.0	3

#	ARTICLE	IF	CITATIONS
73	Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords. <i>Clinical Infectious Diseases</i> , 2022, 74, 1686-1690.	2.9	3
74	Transcriptional Changes in CD8+ T Cells During Antiretroviral Therapy Intensified With Raltegravir. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv045.	0.4	2
75	Case 11-2019: A 49-Year-Old Man with HIV Infection and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2019, 380, 1464-1472.	13.9	2
76	Associations Between Multiple Measures of HIV-1 Persistence in Persons on Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2022, 225, 2163-2166.	1.9	2
77	541HIV Rebound Kinetics and CD4+ T-Cell Loss after Treatment Interruption: A Pooled Analysis of Six AIDS Clinical Trials Group (ACTG) Studies. <i>Open Forum Infectious Diseases</i> , 2014, 1, S23-S23.	0.4	1
78	108. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, S183-S183.	0.4	1
79	Case 20-2017 " A 48-Year-Old Man with Weight Loss, Confusion, Skin Lesions, and Pancytopenia. <i>New England Journal of Medicine</i> , 2017, 376, 2580-2589.	13.9	0
80	HIV-2 Infection: Latest Advances. <i>Current Treatment Options in Infectious Diseases</i> , 2019, 11, 233-242.	0.8	0
81	Case 27-2020: A 53-Year-Old Woman with Headache and Gait Imbalance. <i>New England Journal of Medicine</i> , 2020, 383, 859-866.	13.9	0
82	Antiretroviral Drug Recommendations for HIV Treatment and Prevention"Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 889.	3.8	0
83	Importance of global communication to combat global pandemics: Lessons from the HIV Online Provider Education programme. <i>Southern African Journal of HIV Medicine</i> , 2021, 22, 1281.	0.3	0
84	COVID-19 Treatments for Nonhospitalized Patients"Reply. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 2248.	3.8	0